Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corpor...(ebcast can be accessed on the Events p...)

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information, please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements, including statements regarding the Company's financial position and results of operations, business objectives and drug development plans; the timing of the Company's announcement of top-line results of its Phase 3 SPEAR trial and the initiation of submission of a rolling NDA if the results are positive; the potential safety and efficacy of the Company's picoplatin products in development; and the Company's capital raising, commercialization and partnering goals and strategies. The Company's actual results may differ materially from those indicated in these fo
'/>"/>